Review on the clinical use of eribulin mesylate for the treatment of breast cancer

References

• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger. Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23(Suppl 6):vi46–51.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Gluck S, Faria C, et al. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting. Clin Ther. 2015;37:134–144.
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–923.
   PubMed Web of Science ®Google Scholar
• Chan K-S, Koh C-G, Li H-Y. Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis. 2012;3:e411.
   PubMed Web of Science ®Google Scholar
• Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod. 2009;72:507–515.
   PubMed Web of Science ®Google Scholar
• Eisai. 2010. I. HALAVEN FULL PRESCRIBING INFORMATION. [cited 2015 Nov]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf.
   Google Scholar
• Eisai. 2015. HALAVEN® (eribulin mesylate) Injection (HIGHLIGHTS OF PRESCRIBING INFORMATION). [cited 2015 Nov]. Available from: http://www.halaven.com/Pdfs/HALAVEN-Full-Prescribing-Information-2015.pdf.
   Google Scholar
• Pean E, Klaar S, Berglund EG, et al. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res. 2012;18:4491–4497.
   PubMed Web of Science ®Google Scholar
• Scarpace SL. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer. Clin Ther. 2012;34:1467–1473.
   PubMed Web of Science ®Google Scholar
• Waller CF, Vynnychenko I, Bondarenko I, et al. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2015;16:92–99.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Kravetz S, Jia X, et al. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer. 2012;118:2403–2410.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Molife LR, Sonpavde G, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol. 2012;23:1241–1249.
   PubMed Web of Science ®Google Scholar
• Renouf DJ, Tang PA, Major P, et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs. 2012;30:1203–1207.
   PubMed Web of Science ®Google Scholar
• Arnold SM, Moon J, Williamson SK, et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs. 2011;29:352–359.
   PubMed Web of Science ®Google Scholar
• Maki RG. Eribulin in soft-tissue sarcomas. Lancet Oncol. 2011;12:988–989.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12:1045–1052.
   PubMed Web of Science ®Google Scholar
• Hirata YUD, Uemura D. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl Chem. 1986;58:701–710.
   Web of Science ®Google Scholar
• Pettit GR, Herald CL, Boyd MR, et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem. 1991;34:3339–3340.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–1095.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110:1497–1505.
   PubMed Web of Science ®Google Scholar
• Agoulnik SI, Kawano S, Taylor N, et al. Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. Vasc Cell. 2014;6:3.
   PubMedGoogle Scholar
• Funahashi Y, Okamoto K, Adachi Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105:1334–1342.
   PubMed Web of Science ®Google Scholar
• Gavert N, Ben-Ze’ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med. 2008;14:199–209.
   PubMed Web of Science ®Google Scholar
• Dybdal-Hargreaves NF. 2015. Eribulin affects E-cadherin localization consistent with a reversal of the epithelial-to-mesenchymal transition. In 2015 San Antonio Breast Cancer Symposium. San Antonio (TX): University of Texas Health Science Center at San Antonio.
   Google Scholar
• Jung H-Y, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21:962–968.
   PubMed Web of Science ®Google Scholar
• Thara E, Gitlitz BJ. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy. Future Oncol. 2014;10:1913–1924.
   PubMed Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013–1021.
   PubMed Web of Science ®Google Scholar
• Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther. 1992;55:31–51.
   PubMed Web of Science ®Google Scholar
• Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009;15:4207–4212.
   PubMed Web of Science ®Google Scholar
• Dubbelman A-C, Rosing H, Jansen RS, et al. Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors. Drug Metab Dispos. 2012;40:313–321.
   PubMed Web of Science ®Google Scholar
• Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health. 2015;7:47–58.
   PubMed Web of Science ®Google Scholar
• Polastro L, Aftimos PG, Awada A. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Rev Anticancer Ther. 2014;14:649–665.
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27:2954–2961.
   PubMed Web of Science ®Google Scholar
• Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28:3922–3928.
   PubMed Web of Science ®Google Scholar
• Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23:1441–1448.
   PubMed Web of Science ®Google Scholar
• McIntyre K, O’Shaughnessy J, Schwartzberg L, et al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat. 2014;146:321–328.
   PubMed Web of Science ®Google Scholar
• Smith JW 2nd, Vukelja S, Hoffman AD, et al. Phase II, multicenter, single-arm, feasibility study of eribulin combined with capecitabine for adjuvant treatment in estrogen receptor-positive, early-stage breast cancer. Clin Breast Cancer. 2016;16:31–37.
   PubMedGoogle Scholar
• Kaklamani VG, Jeruss JS, Hughes E, et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015;151:629–638.
   PubMed Web of Science ®Google Scholar
• Wilks S, Puhalla S, O’Shaughnessy J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer. 2014;14:405–412.
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Garcia AA, Vogel C, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140:341–351.
   PubMed Web of Science ®Google Scholar
• Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594–601.
   PubMed Web of Science ®Google Scholar
• Mukohara T, Nagai S, Mukai H, et al. Eribulin mesylate in patients with refractory cancers: a phase I study. Invest New Drugs. 2012;30:1926–1933.
   PubMed Web of Science ®Google Scholar
• Synold TWMR, Newman EM, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. ASCO Meet Abstr [Internet]. 2005;23(16_suppl):3036. Available from: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/3036
   Google Scholar
• Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009;15:4213–4219.
   PubMed Web of Science ®Google Scholar
• Donoghue M, Lemery SJ, Yuan W, et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a “physician’s choice” control arm in a randomized approval trial. Clin Cancer Res. 2012;18:1496–1505.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73–80.
   PubMed Web of Science ®Google Scholar
• Chalasani P 2014. Metronomic eribulin in metastatic breast cancer. Abstract OT2-2-05
   Google Scholar
• Kaklamani V, o’Regan R, Wisinski K, et al. Abstract OT2-2-02: phase I/II clinical trial on the combination of carboplatin, eribulin and E7449. Cancer Res [Internet]. 2015;75(9 Supplement):OT2–2–02–OT2–2–02. Available from: http://cancerres.aacrjournals.org/content/75/9_Supplement/OT2-2-02.short
   Web of Science ®Google Scholar
• Mukai H, Saeki T, Shimada K, et al. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. Invest New Drugs. 2015;33:119–127.
   PubMed Web of Science ®Google Scholar
• Freedman R. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32:5s. (suppl; abstr TPS668).
   Google Scholar
• Barnato S. Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer. J Clin Oncol. 2012;30. (suppl; abstr TPS1134).
   Web of Science ®Google Scholar
• Abraham J. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9. J Clin Oncol. 2014;32:5s. (suppl; abstr 1058).
   Google Scholar
• Metzger-Filho O. A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes. J Clin Oncol. 2014;32:5s. (suppl; abstr TPS1138).
   Google Scholar
• Traina T. Phase 2 feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate with or without prophylactic growth factor (GF) for adjuvant treatment of early-stage breast cancer (EBC). J Clin Oncol. 2014;32:5s. (suppl; abstr TPS670^).
   Google Scholar
• Muss H, Cortes J, Vahdat LT, et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist. 2014;19:318–327.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Ripamonti B, Bruyas A, et al. Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging. 2015;10:157–174.
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–3414.
   PubMed Web of Science ®Google Scholar
• Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92:2267–2272.
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542–5551.
   PubMed Web of Science ®Google Scholar
• Tan AR, Sarantopoulos J, Lee L, et al. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol. 2015;76:1051–1061.
   PubMed Web of Science ®Google Scholar
• Cortes J, Hudgens S, Twelves C, et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015;154:509–520.
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Overcoming resistance to targeted anticancer drugs. N Engl J Med. 2013;369:1852–1853.
   PubMed Web of Science ®Google Scholar
• Dezso Z, Oestreicher J, Weaver A, et al. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One. 2014;9:e106131.
   PubMed Web of Science ®Google Scholar
• NICE. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE - Final appraisal determination Eribulin for the treatment of locally advanced or metastatic breast cancer. Natl Inst Heal Clin Excell [Internet]. 2012 [June];1–47. Available from: https://www.nice.org.uk/guidance/ta250/documents/breast-cancer-advanced-eribulin-final-appraisal-determination-document2
   Google Scholar
• Majethia U. Cost effectiveness analysis of eribulin mesylate as a treatment for metastatic breast cancer in Spain: management in the later lines of therapy. Value Heal [Internet]. 2015;18(3):A203. Available from: http://www.researchgate.net/publication/276506374_PCN78._Cost_Effectiveness_Analysis_of_Eribulin_Mesylate_as_a_Treatment_for_Metastatic_Breast_Cancer_In_Spain_Management_in_the_Later_Lines_of_Therapy
   Google Scholar
• pCODR. 2012. pan-Canadian oncology drug review final economic guidance report eribulin (Halaven) for metastatic breast cancer. Pan-Canadian Oncol Drug Rev [Internet]. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr-halavenmb-fn-egr.pdf
   Google Scholar
• NCPE. Cost effectiveness of eribulin (Halaven ®) for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Natl Cent Pharmacoeconomics [Internet]. 2012 [December]; Available from: http://www.ncpe.ie/wp-content/uploads/2011/03/Eribulin-Halaven-Summary1.pdf
   Google Scholar